INTRODUCTION: The impacts of prurigo nodularis (PN) on healthcare resource utilization (HCRU) and associated costs are unclear. METHODS: This retrospective, cross-sectional claims analysis (IQVIA PharMetrics RESULTS: We matched 16,888 patients with PN with 16,888 controls. Most comorbidities (mental health, metabolic conditions, type 2 inflammatory diseases) appeared more frequently in patients with PN versus controls. HCRU was significantly (P <
0.001) higher for patients with PN versus controls, including mean (standard deviation, SD) number of outpatient visits (17.0 [15.5] vs 8.1 [10.7]) and proportion of patients with hospitalizations (9.3% vs 5.9%). Mean (SD) total costs were significantly (P <
0.001) greater for patients with PN versus controls (8,315 [6,476] vs 451 [0,982]). CONCLUSIONS: Patients with PN receiving advanced therapy had higher HCRU and costs versus localized/no therapy. Patients with PN (particularly those receiving advanced therapies) incurred higher all-cause HCRU burden and associated costs than matched controls. Enhanced feature (slides, video, animation) (MP4 12313 KB).